Last €11.94 EUR
Change Today -0.41 / -3.32%
Volume 214.1K
REC On Other Exchanges
Symbol
Exchange
REC is not on other exchanges.
As of 11:30 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (REC) Snapshot

Open
€12.31
Previous Close
€12.35
Day High
€12.31
Day Low
€11.94
52 Week High
02/28/14 - €13.35
52 Week Low
09/5/13 - €8.40
Market Cap
2.5B
Average Volume 10 Days
175.4K
EPS TTM
€0.72
Shares Outstanding
209.1M
EX-Date
04/28/14
P/E TM
16.7x
Dividend
€0.33
Dividend Yield
2.76%
Current Stock Chart for RECORDATI SPA (REC)

Related News

No related news articles were found.

recordati spa (REC) Related Businessweek News

No Related Businessweek News Found

recordati spa (REC) Details

Recordati S.p.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, analgesia, antipyretics, cold preparations, radio contrast agent, and generics. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. It also develops Zanipress for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Cystadrops that is under Pre-registration in the European Union for the treatment of ocular cystinosis. In addition, the company develops REC 0438 for the treating overactive bladder in patients with spinal lesions and is under Phase I clinical trials; methadone for treating Cancer related pain and is under Phase IIIb clinical trials; Citrafleet for colonoscopy and is under Phase III clinical trials; and GRASPA for Acute lymphoblastic leukemia and is under Phase II/III clinical trials, as well as for Acute myeloid leukemia and is under Phase II b clinical trials. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.

3,961 Employees
Last Reported Date: 03/7/14
Founded in 1926

recordati spa (REC) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

recordati spa (REC) Key Developments

Recordati SpA Announces Consolidated Earnings Results for the First Half Year Ended June 30, 2014

Recordati SpA announced consolidated earnings results for the first half year ended June 30, 2014. For the period, the company reported revenue of EUR 507.6 million, up by 6.3% compared to the same period of the preceding year. EBITDA at 27.9% of sales, is EUR 141.9 million, an increase of 18.2% over the same period of the preceding year. Operating income, at 24.0% of sales, is EUR 121.8 million, an increase of 18.8%. Net income, at 16.4% of sales, is EUR 83.0 million, an increase of 18.1% over the first half of 2013.

Recordati SpA, H1 2014 Earnings Call, Jul 29, 2014

Recordati SpA, H1 2014 Earnings Call, Jul 29, 2014

Recordati Receives Orphan Drug Designation in the U.S. for Organic Acidemias

Recordati announced that the U.S. Food and Drug Administration (FDA) has granted approval of Orphan Europe's request for orphan drug designation for the use of Carbaglu(R) (carglumic acid) in the treatment of organic acidemias (OAs). The term organic acidemias (OAs) applies to a group of serious life-threatening disorders characterized by excretion of non-amino organic acids in urine. Most organic acidemias (OAs) result from dysfunction of a specific step in amino acid catabolism usually the result of deficient enzyme activity. Classic organic acidemias (OAs) such as isovaleric acidemia (IVA), propionic acidemia (PA) and methylmalonic acidemia (MMA) are autosomal recessive disorders of branched-chain amino acid metabolism (leucine, isoleucine, valine). Orphan drug designation applies to drugs that seek to treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. while providing significant therapeutic advantage over existing therapies. The designation provides the opportunity for seven years marketing exclusivity upon approval for the designated indication, tax credits to offset clinical research expenses, the ability to apply for annual grant funding, and the potential waiver of prescription drug user fees.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REC:IM €11.94 EUR -0.41

REC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.38 EUR -0.05
Faes Farma SA €2.06 EUR -0.02
Ipsen SA €32.85 EUR -0.345
Meda AB kr105.00 SEK -6.30
Orion OYJ €27.73 EUR -0.04
View Industry Companies
 

Industry Analysis

REC

Industry Average

Valuation REC Industry Range
Price/Earnings 18.0x
Price/Sales 2.5x
Price/Book 3.2x
Price/Cash Flow 17.8x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit www.recordati.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.